---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-014265"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2023-04-28T23:59:59+00:00"
generated_at: "2026-06-16T06:09:17.868753+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Cumberland shareholders elect directors, ratify auditor, approve say-on-pay and incentive plan amendment

## Summary
- Class I directors Krogulski (99.1%) and Young (90.7%) elected; Class II director Brown (98.6%) elected.
- Ratification of FORVIS as auditor for 2023 received 99.1% votes in favor.
- Advisory say-on-pay resolution approved with 89.9% votes in favor.
- Amendment to 2007 Long-Term Incentive Plan approved with 75.0% votes in favor.

## SEC filing metadata
- accession: 0001628280-23-014265
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2023-04-28T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828023014265/0001628280-23-014265-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828023014265/cpix-20230425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-014265
- JSON: https://secwatch.observer/filing/0001628280-23-014265.json
- Plain text: https://secwatch.observer/filing/0001628280-23-014265.txt

## Key facts
- Shareholder Votes
  CUMBERLAND PHARMACEUTICALS INC shareholders approved Approval of an amendment to the Amended and Restated 2007 Long-Term Incentive Compensation Plan at the 2023-04-25 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-04-25
  source text: Approve an amendment to the amended and restated 2007 long-term incentive compensation plan 6,869,796 2,286,706 — 26,353 75.0%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000162828023014265/0001628280-23-014265-index.htm
- Shareholder Votes
  CUMBERLAND PHARMACEUTICALS INC shareholders approved Resolution regarding compensation of the named executive officers at the 2023-04-25 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-04-25
  source text: Resolution regarding compensation of named officers 8,228,888 926,046 — 27,921 89.9%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000162828023014265/0001628280-23-014265-index.htm
- Shareholder Votes
  CUMBERLAND PHARMACEUTICALS INC shareholders approved Ratification of the appointment of FORVIS, LLP as independent registered public accounting firm for the year ending December 31, 2023 at the 2023-04-25 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-04-25
  source text: Appointment of FORVIS, LLP as our independent registered public accounting firm for the year ending December 31, 2023 11,474,731 107,830 — 17,830 99.1%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000162828023014265/0001628280-23-014265-index.htm
- Shareholder Votes
  CUMBERLAND PHARMACEUTICALS INC shareholders approved Election of Directors at the 2023-04-25 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-04-25
  source text: The voting results were as follows: For Against Withheld Abstentions % of Votes in Favor Kenneth J. Krogulski 9,100,390 — 82,465 — 99.1% Caroline R. Young 8,326,006 — 856,849 — 90.7% Martin S. Brown, Jr. 9,053,642 — 129,213 — 98.6%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000162828023014265/0001628280-23-014265-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.